Pharmacological interventions for improving adenovirus usage in gene therapy

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 50-55

  Haisma, Hidde J ^a   Rita Bellu, Anna ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Adenoviruses; Gene therapy; Kupffer cells; Systemic administration

Indexed keywords

ADAPTOR PROTEIN; ADENOVIRAL PENTON BASE PROTEIN; ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CLODRONIC ACID; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COPOLYMER; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GADOLINIUM CHLORIDE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROGOL; MEMBRANE COFACTOR PROTEIN; NEUTRALIZING ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; POLYINOSINIC ACID; PROTEIN C; PROTEOHEPARAN SULFATE; PROTHROMBIN; SCAVENGER RECEPTOR A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN; VIRUS PROTEIN; VIRUS RECEPTOR; WARFARIN;

ADENOVIRUS 5; AMINO ACID SEQUENCE; BINDING AFFINITY; CHEMICAL MODIFICATION; ENDOTHELIUM CELL; ERYTHROCYTE; GENE EXPRESSION; GENE REPLICATION; HUMAN; IN VIVO GENE TRANSFER; KUPFFER CELL; LIVER CELL; MACROPHAGE; NEUTROPHIL; NONHUMAN; PATHOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ADENOVIRIDAE; GENE THERAPY; HEPATOCYTES; HUMANS; KUPFFER CELLS;

EID: 79952960255     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100310h     Document Type: Review

References (63)

1. Edelstein, M. L.; Abedi, M. R.; Wixon, J. Gene therapy clinical trials worldwide to 2007san update. J. Gene Med. 2007, 9 (10), 833-42. (Pubitemid 47543250)
2. Chroboczek, J.; Ruigrok, R. W.; Cusack, S. Adenovirus fiber. Curr. Top. Microbiol. Immunol. 1995, 199 (Part 1), 163-200.
3. Sharma, A.; Li, X.; Bangari, D. S.; Mittal, S. K. Adenovirus receptors and their implications in gene delivery. Virus Res. 2009, 143 (2), 184-94.
4. Liszewski, M. K.; Post, T. W.; Atkinson, J. P. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 1991, 9, 431-55.
5. Bergelson, J. M.; Cunningham, J. A.; Droguett, G.; Kurt-Jones, E. A.; Krithivas, A.; Hong, J. S.; et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275 (5304), 1320-3. (Pubitemid 27114163)
6. Tomko, R. P.; Xu, R.; Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (7), 3352-6. (Pubitemid 27157315)
7. Bewley, M. C.; Springer, K.; Zhang, Y. B.; Freimuth, P.; Flanagan, J. M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999, 286 (5444), 1579-83.
8. Wickham, T. J.; Mathias, P.; Cheresh, D. A.; Nemerow, G. R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73 (2), 309-19. (Pubitemid 23123309)
9. Wang, K.; Huang, S.; Kapoor-Munshi, A.; Nemerow, G. Adenovirus internalization and infection require dynamin. J. Virol. 1998, 72 (4), 3455-8. (Pubitemid 28175599)
10. Muruve, D. A.; Barnes, M. J.; Stillman, I. E.; Libermann, T. A. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 1999, 10 (6), 965-76. (Pubitemid 29195426)
11. Zhang, Y.; Chirmule, N.; Gao, G. P.; Qian, R.; Croyle, M.; Joshi, B.; et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 2001, 3 (5 Part 1), 697-707. (Pubitemid 32509867)
12. Muruve, D. A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 2004, 15 (12), 1157-66. (Pubitemid 40052429)
13. Cotter, M. J.; Muruve, D. A. The induction of inflammation by adenovirus vectors used for gene therapy. Front. Biosci. 2005, 10, 1098-105.
14. Nemerow, G. R. A new link between virus cell entry and inflammation: adenovirus interaction with integrins induces specific proinflammatory responses. Mol. Ther. 2009, 17 (9), 1490-1.
15. Shayakhmetov, D. M.; Li, Z. Y.; Ni, S.; Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 2004, 78 (10), 5368-81. (Pubitemid 38581487)
16. Worgall, S.; Wolff, G.; Falck-Pedersen, E.; Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 1997, 8 (1), 37-44. (Pubitemid 27075341)
17. Lieber, A.; He, C. Y.; Meuse, L.; Schowalter, D.; Kirillova, I.; Winther, B.; et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 1997, 71 (11), 8798-807. (Pubitemid 27446464)
18. Alemany, R.; Suzuki, K.; Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81 (Part 11), 2605-9.
19. Tao, N.; Gao, G. P.; Parr, M.; Johnston, J.; Baradet, T.; Wilson, J. M.; et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 2001, 3 (1), 28-35. (Pubitemid 32509802)
20. Wolff, G.; Worgall, S.; van Rooijen, N.; Song, W. R.; Harvey, B. G.; Crystal, R. G. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J. Virol. 1997, 71 (1), 624-9. (Pubitemid 26412334)
21. Smith, J. S.; Xu, Z.; Byrnes, A. P. A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J. Virol. Methods 2008, 147 (1), 54-60. (Pubitemid 350250848)
22. Schiedner, G.; Hertel, S.; Johnston, M.; Dries, V.; van Rooijen, N.; Kochanek, S. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol. Ther. 2003, 7 (1), 35-43. (Pubitemid 36305357)
23. Ziegler, R. J.; Li, C.; Cherry, M.; Zhu, Y.; Hempel, D.; van Rooijen, N.; et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum. Gene Ther. 2002, 13 (8), 935-45. (Pubitemid 34539370)
24. Alemany, R.; Curiel, D. T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 2001, 8 (17), 1347-53. (Pubitemid 32834304)
25. Smith, T. A.; Idamakanti, N.; Marshall-Neff, J.; Rollence, M. L.; Wright, P.; Kaloss, M.; et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 2003, 14 (17), 1595-604. (Pubitemid 37452870)
26. Smith, T. A.; Idamakanti, N.; Rollence, M. L.; Marshall-Neff, J.; Kim, J.; Mulgrew, K.; et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 2003, 14 (8), 777-87. (Pubitemid 36623514)
27. Martin, K.; Brie, A.; Saulnier, P.; Perricaudet, M.; Yeh, P.; Vigne, E. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 2003, 8 (3), 485-94. (Pubitemid 37161470)
28. Mizuguchi, H.; Koizumi, N.; Hosono, T.; Ishii-Watabe, A.; Uchida, E.; Utoguchi, N.; et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 2002, 9 (12), 769-76. (Pubitemid 34679304)
29. Liu, Q.; Zaiss, A. K.; Colarusso, P.; Patel, K.; Haljan, G.; Wickham, T. J.; et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 2003, 14 (7), 627-43. (Pubitemid 36543435)
30. Haisma, H. J.; Kamps, J. A.; Kamps, G. K.; Plantinga, J. A.; Rots, M. G.; Bellu, A. R. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J. Gen. Virol. 2008, 89 (Part 5), 1097-105.
31. Manickan, E.; Smith, J. S.; Tian, J.; Eggerman, T. L.; Lozier, J. N.; Muller, J.; et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol. Ther. 2006, 13 (1), 108-17. (Pubitemid 41763488)
32. Haisma, H. J.; Boesjes, M.; Beerens, A. M.; van der Strate, B. W.; Curiel, D. T.; Pluddemann, A.; et al. Scavenger receptor A: a new route for adenovirus 5. Mol. Pharmaceutics 2009, 6 (2), 366-74.
33. Lyons, M.; Onion, D.; Green, N. K.; Aslan, K.; Rajaratnam, R.; Bazan-Peregrino, M.; et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 2006, 14 (1), 118-28. (Pubitemid 44191831)
34. Shayakhmetov, D. M.; Gaggar, A.; Ni, S.; Li, Z. Y.; Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005, 79 (12), 7478-91. (Pubitemid 40756784)
35. Di Paolo, N. C.; Kalyuzhniy, O.; Shayakhmetov, D. M. Fiber shaftchimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J. Virol. 2007, 81 (22), 12249-59. (Pubitemid 350085840)
36. Parker, A. L.; Waddington, S. N.; Nicol, C. G.; Shayakhmetov, D. M.; Buckley, S. M.; Denby, L.; et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 2006, 108 (8), 2554-61.
37. Parker, A. L.; McVey, J. H.; Doctor, J. H.; Lopez-Franco, O.; Waddington, S. N.; Havenga, M. J.; et al. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J. Virol. 2007, 81 (7), 3627-31. (Pubitemid 46456671)
38. Waddington, S. N.; McVey, J. H.; Bhella, D.; Parker, A. L.; Barker, K.; Atoda, H.; et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132 (3), 397-409. (Pubitemid 351200513)
39. Alba, R.; Bradshaw, A. C.; Parker, A. L.; Bhella, D.; Waddington, S. N.; Nicklin, S. A.; et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 2009, 114 (5), 965-71.
40. Kalyuzhniy, O.; Di Paolo, N. C.; Silvestry, M.; Hofherr, S. E.; Barry, M. A.; Stewart, P. L.; et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (14), 5483-8. (Pubitemid 351753889)
41. Gimenez-Alejandre, M.; Cascallo, M.; Bayo-Puxan, N.; Alemany, R. Coagulation factors determine tumor transduction in vivo. Hum. Gene Ther. 2008, 19 (12), 1415-9.
42. Liu, Y.; Wang, H. J.; Yumul, R.; Gao, W. T.; Gambotto, A.; Morita, T.; et al. Transduction of Liver Metastases After Intravenous Injection of Ad5/35 or Ad35 Vectors With and Without Factor X-Binding Protein Pretreatment. Hum. Gene Ther. 2009, 20 (6), 621-9.
43. Jonsson, M. I.; Lenman, A. E.; Frangsmyr, L.; Nyberg, C.; Abdullahi, M.; Arnberg, N. Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J. Virol. 2009, 83 (8), 3816-25.
44. Othman, M.; Labelle, A.; Mazzetti, I.; Elbatarny, H. S.; Lillicrap, D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 2007, 109 (7), 2832-9. (Pubitemid 46482078)
45. Stone, D.; Liu, Y.; Shayakhmetov, D.; Li, Z. Y.; Ni, S.; Lieber, A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 2007, 81 (9), 4866-71. (Pubitemid 46668683)
46. Shimony, N.; Elkin, G.; Kolodkin-Gal, D.; Krasny, L.; Urieli- Shoval, S.; Haviv, Y. S. Analysis of adenoviral attachment to human platelets. Virol. J. 2009, 6, 25.
47. Seiradake, E.; Henaff, D.; Wodrich, H.; Billet, O.; Perreau, M.; Hippert, C.; et al. The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009, 5 (1), e1000277.
48. Grill, J.; Van Beusechem, B. W.; Van Der Valk, P.; Dirven, C. M. F.; Leonhart, A.; Pherai, D. S.; et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 2001, 7 (3), 641-50. (Pubitemid 32707990)
49. Miller, C. R.; Buchsbaum, D. J.; Reynolds, P. N.; Douglas, J. T.; Gillespie, G. Y.; Mayo, M. S.; et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 1998, 58 (24), 5738-48. (Pubitemid 29006415)
50. Witlox, M. A.; Van Beusechem, V. W.; Grill, J.; Haisma, H. J.; Schaap, G.; Bras, J.; et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med. 2002, 4 (5), 510-6. (Pubitemid 40268377)
51. Dmitriev, I.; Kashentseva, E.; Rogers, B. E.; Krasnykh, V.; Curiel, D. T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 2000, 74 (15), 6875-84. (Pubitemid 30470671)
52. Douglas, J. T.; Rogers, B. E.; Rosenfeld, M. E.; Michael, S. I.; Feng, M.; Curiel, D. T. Targeted gene delivery by tropismmodified adenoviral vectors. Nat. Biotechnol. 1996, 14 (11), 1574-8. (Pubitemid 26365552)
53. Doukas, J.; Hoganson, D. K.; Ong, M.; Ying, W.; Lacey, D. L.; Baird, A.; et al. Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J. 1999, 13 (11), 1459-66. (Pubitemid 29382513)
54. Haisma, H. J.; Pinedo, H. M.; Rijswijk, A.; der Meulen-Muileman, I.; Sosnowski, B. A.; Ying, W.; et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther. 1999, 6 (8), 1469-74. (Pubitemid 29396735)
55. Haisma, H. J.; Grill, J.; Curiel, D. T.; Hoogeland, S.; van Beusechem, V. W.; Pinedo, H. M.; et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther. 2000, 7 (6), 901-4. (Pubitemid 30437291)
56. Nettelbeck, D. M.; Rivera, A. A.; Volk, A. L.; Balague, C.; Davydova, J.; Yamamoto, M.; et al. Engineering of oncolytic adenoviruses for targeted and efficient virotherapy of malignant melanoma. Mol. Ther. 2003, 7 (5), S355-S356.
57. Haisma, H. J.; Kamps, G. K.; Bouma, A.; Geel, T. M.; Rots, M. G.; Kariath, A.; et al. Selective targeting of adenovirus to alphavbeta3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. Int. J. Pharm. 2010, 391 (1-2), 155-61.
58. Carette, J. E.; Graat, H. C.; Schagen, F. H.; Mastenbroek, D. C.; Rots, M. G.; Haisma, H. J.; et al. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology 2007, 361 (1), 56-67. (Pubitemid 46551227)
59. Bayo-Puxan, N.; Gimenez-Alejandre, M.; Lavilla-Alonso, S.; Gros, A.; Cascallo, M.; Hemminki, A.; et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum. Gene Ther. 2009, 20 (10), 1214-21.
60. Fisher, K. D.; Stallwood, Y.; Green, N. K.; Ulbrich, K.; Mautner, V.; Seymour, L. W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8 (5), 341-8. (Pubitemid 32241933)
61. Ogawara, K.; Rots, M. G.; Kok, R. J.; Moorlag, H. E.; Van Loenen, A. M.; Meijer, D. K.; et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 2004, 15 (5), 433-43. (Pubitemid 38639615)
62. van Rooijen, N.; van Kesteren-Hendrikx, E. "In vivo" depletion of macrophages by liposome-mediated "suicide". Methods Enzymol. 2003, 373, 3-16. (Pubitemid 41103273)
63. Di Paolo, N. C.; van Rooijen, N.; Shayakhmetov, D. M. Redundant and synergistic mechanisms control the sequestration of bloodborn adenovirus in the liver. Mol. Ther. 2009, 17 (4), 675-84.